The advent of anti-vascular endothelial growth factor (VEGF) designed for intraocular injection has revolutionised the treatment of neovascular age-related macular degeneration (nAMD), the leading cause of severe vision loss in the elderly population. This evidence concerns the gene VEGFA and wet macular degeneration.